title: Comparison of Geographic Atrophy Growth Rates Using Different Imaging Modalities in the COMPLETE Study.
abstract: OBJECTIVE
  To compare the measurements and growth rates of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) obtained using different imaging modalities.
  
  
  METHODS
  Thirty patients with AMD and GA measuring from 1.25 mm² to 18 mm² based on spectral-domain optical coherence tomography (SD-OCT) fundus imaging were enrolled. Imaging was performed at baseline and at follow-up months 3, 6, 9, and 12, including autofluorescence (AF) imaging with a fundus camera-based flash system (TRC-50DX; Topcon Medical Systems, Oakland, NJ; AF excitation λ: 535-585 nm; detection λ: 605-715 nm), AF and fluorescein angiography (FA) imaging with a confocal scanning laser ophthalmoscopy (SLO) system (Spectralis; Heidelberg Engineering, Heidelberg, Germany; AF excitation λ: 488 nm; detection λ: > 500 nm), and SD-OCT en face imaging (Cirrus; Carl Zeiss Meditec, Dublin, CA).
  
  
  RESULTS
  Average baseline square root measurements and enlargement rates of square root areas appeared similar across all modalities; 0.2 mm was the largest difference between any pair of measurement means. The intraclass correlation coefficients (ICC) were essentially equal to 1 for all comparisons of area measurements but were lower for growth rates than area measurements. Comparison of 26-week average enlargement rates showed no significant difference between the SLO AF image and enhanced SD-OCT en face image (mean difference: 0.01 mm; SD: 0.10; P = .70).
  
  
  CONCLUSIONS
  Agreement among all imaging modalities in measuring the areas of GA at baseline diminished when the growth rates of GA were compared over 26 weeks, likely because each imaging technique identifies different anatomic features along the border of GA, which may appear similar but change at different rates.
authors.forename: Zohar
authors.initials: Z
authors.lastname: Yehoshua
authors.forename: Carlos Alexandre
authors.initials: CA
authors.lastname: de Amorim Garcia Filho
authors.forename: Renata Portella
authors.initials: RP
authors.lastname: Nunes
authors.forename: Giovanni
authors.initials: G
authors.lastname: Gregori
authors.forename: Fernando M
authors.initials: FM
authors.lastname: Penha
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Moshfeghi
authors.forename: SriniVas
authors.initials: S
authors.lastname: Sadda
authors.forename: William
authors.initials: W
authors.lastname: Feuer
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Rosenfeld
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D051056:Complement Inactivating Agents / Q000627:therapeutic use; D004311:Double-Blind Method; D005451:Fluorescein Angiography; D057092:Geographic Atrophy / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D008875:Middle Aged; D064847:Multimodal Imaging; D009887:Ophthalmoscopy; D061848:Optical Imaging; D011446:Prospective Studies; D012160:Retina / Q000473:pathology*; D041623:Tomography, Optical Coherence
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D051056:Complement Inactivating Agents; C481642:eculizumab